Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

NCT05984199 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Funding

Conditions

Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL: VCAR33

Sponsor

Vor Biopharma